Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.
Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.
Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.
Practice Harm Reduction. Proceed with Caution.
Also known as:
hoxyphenyl)-2-propa[German][ACD/IUPAC Name] namin
thoxyphenyl)-2-prop[ACD/IUPAC Name] anamine
thoxyphényl)-2-prop[French][ACD/IUPAC Name] anamine
4-bromo-2,5-dimetho[ACD/Index Name] xy-α-methyl-
4-bromo-2,5-dimetho xy-α-methyl-, (±)-
- BROLAMFETAMINE, (R)-
- BROLAMFETAMINE, (S)-
DOB is a relatively uncommon synthetic psychedelic. It is best known for its very low doses and long duration. Historically it has rarely been taken deliberately, but in place of LSD, however it has recently found its own place in the research chemical scene.
It is a member of the DOx family of psychedelic amphetamines. While DOB had first been synthesized in 1967 and briefly tested in 1971, it took until the 1991 publication of the book PiHKAL ("Phenethylamines I Have Known And Loved") by Alexander Shulgin to be documented in-depth. Today, DOB is used as a recreational drug and an entheogen.
It is still rarely sold online but is more commonly found in the streets the form of misrepresented LSD due to its ability to fit onto similar-sized blotter paper. Very little data exists about the pharmacological properties, metabolism, and toxicity of DOB in humans. Along with its sensitive dose-response, unusually long and unpredictable duration, many reports also suggest that this substance may be overly difficult to use safely for those who are not already very experienced with using hallucinogens.
It is highly advised to use harm reduction practices if using this substance.
Amphetamines are substituted phenethylamines containing a phenyl ring bound to an amino (NH2) group through an ethyl chain and a methyl group bound to the alpha carbon Rα.
DOB contains methoxy functional groups OCH3 attached to carbons R2 and R5 as well as a bromine atom attached to carbon R4 of the phenyl ring.
DOB is the amphetamine analogue of the phenethylamine 2C-B.
|Avg. Mass||274.1542 Da|
|Monoisotopic Mass||273.036438 Da|
|DOB Duration Data|
Interactions and Synergies
- The 5-MeO class of tryptamines can be unpredictable in their interactions, particularly increasing the risk of unpleasant physical side effects.
- Cannabis has an unexpectedly strong and somewhat unpredictable synergy with psychedelics.
- As an NMDA antagonist MXE potentiates DOx which can be unpleasantly intense
- The combined stimulating effects of the two can be uncomfortable. Coming down on the MDMA while the DOx is still active can be quite anxiogenic.
- High doses of caffeine may cause anxiety which is less manageable when tripping, and since both are stimulating it may cause some physical discomfort.
- MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably
- The DOx class as psychedelic stimulants have the potential to mask the effects of DXM and could lead to redosing to an unsafe level. DXM can also potentiate DOx resulting in an unpleasantly intense experience.
- Details of this combination are not well understood but PCP generally interacts in an unpredictable manner.
- The combined stimulating effects of the two can lead to an uncomfortable body-load, while the focusing effects of amphetamine can easily lead to thought loops. Coming down from amphetamines while the DOx is still active can be quite anxiogenic.
- The combined stimulating effects of the two can lead to an uncomfortable body-load, while the focusing effects of cocaine can easily lead to thought loops. Coming down from cocaine while the DOx is still active can be quite anxiogenic
- Tramadol is well known to lower seizure threshold and psychedelics also cause occasional seizures.
- Drinking on stimulants is risky because the sedative effects of the alcohol are reduced, and these are what the body uses to gauge drunkenness. This typically leads to excessive drinking with greatly reduced inhibitions, high risk of liver damage and increased dehydration. They will also allow you to drink past a point where you might normally pass out, increasing the risk.
- No unexpected interactions.
|Effects||Euphoria, empathy, insight, brightened colour, Closed/Open eye visuals, enhanced tactile sensation, mental/physical stimulation, decreased appetite, pupil dilation, restlessness, change in perception, ego softening, sweating/chills, muscle tension, confusion, insomnia.|
|Marguis Test Result||Olive Green - Yellow|
DOB’s psychedelic effects are believed to come from its efficacy at the 5-HT2 receptor family as a partial agonist. DOB appears to be quite selective for the 5-HT2B receptor and is often used in scientific research when studying the 5-HT2 receptor subfamily. It has been suggested that DOB is a prodrug metabolized in the lungs. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
Disclaimer: The effects listed below are cited from the Subjective Effect Index (SEI), which relies on assorted anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Stimulation - DOB is usually considered to be extremely stimulating at levels which do not become overwhelming and are encouraged instead of forced. This results in a shakiness and unsteadiness of the hands at high dosages, but encourages the person to move around, run, dance, climb and generally engage in physical activities. The level of stimulation varies between users with some people reporting it to be somewhat similar to amphetamine in its intensity and others reporting that it is extremely subtle even at higher dosages. In comparison, other more commonly used psychedelics such as psilocin are generally sedating and relaxed.
- Spontaneous bodily sensations - The "body high" of DOB is manifested as somewhat intense in comparison to most classical psychedelics such as LSD. The sensation itself can be described as a constantly present yet somewhat mild energetic pins and needles sensation that encompasses a person’s entire body. It is usually static in its position and felt over every square inch of the skin as if it was coming from behind the user's body. Occasionally, however, it manifests itself in the form of a continuously shifting tingling sensation that travels up and down the body in spontaneous waves.
- Physical euphoria - It should be noted that this effect is not as reliably induced as it is with substances like stimulants or entactogens, and can just as easily manifest as physical discomfort without any apparent reason. DOB and other psychedelic amphetamines tend to lean towards physical dysphoria more so than other psychedelics.
- Changes in felt bodily form
- Bodily control enhancement
- Tactile enhancement - Feelings of enhanced tactile sensation are consistently present at moderate levels throughout most DOB experiences.
- Stamina enhancement
- Bodily pressures
- Temperature regulation suppression
- Abnormal heartbeat
- Increased heart rate
- Increased blood pressure
- Increased perspiration
- Muscle contractions
- Muscle spasms
- Muscle cramps
- Difficulty urinating
- Nausea - Mild to extreme nausea is typically reported when consumed in moderate to high dosages and either passes once the user has vomited or gradually fades by itself as the peak sets in.
- Appetite suppression
- Stomach cramps
- Vasoconstriction - This effect is reported to be more common than with other psychedelics and can feel prominent and uncomfortable.
- Increased salivation
- Pupil dilation
- Teeth grinding
- Restless legs
The head space of DOB is described by many as one of prominent mental stimulation and a powerful enhancement of a person's current mental state. Many users report that it may not be as deep as other traditional psychedelics such as LSD or psilocin and that it is comparatively empty regarding its insightfulness.
- Anxiety & Paranoia
- Analysis enhancement
- Conceptual thinking
- Thought acceleration
- Thought connectivity
- Cognitive euphoria
- Analysis suppression
- Emotion enhancement
- Empathy, affection, and sociability enhancement - This component is inconsistently manifested only in the context of social settings in which one is within the company of others. These feelings of sociability, love and empathy are much weaker and less sharp than those found on substances such as MDMA and 2C-B, but still prove strong enough to provide therapeutic effects.
- Increased music appreciation
- Increased sense of humor
- Immersion enhancement
- Novelty enhancement
- Suggestibility enhancement
- Language suppression
- Memory suppression
- Ego death - While DOB is technically able to produce states of ego dissolution, it tends to more often than not develop only in extremely high doses, with grave physical and mental side effects being apparent and is often of a terrifying nature.
- Time distortion
- Thought loops
- Drifting (melting, flowing, breathing and morphing) - In comparison to other psychedelics, this effect can be described as highly detailed, slow and smooth in motion, static in appearance and unrealistic/cartoon-like in style.
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- After images
- Brightness alteration
DOB visual geometry can be described as more similar in appearance to that of LSD, 25I-NBOMe or 2C-B than that of mescaline, psilocin or DMT. It can be comprehensively described through its variations as intricate in complexity, algorithmic in form, synthetic in feel, brightly lit, multicoloured in scheme, glossy in shading, sharp in edges, large in size, fast in speed, smooth in motion, equally rounded and angular in its corners, non-immersive in-depth and consistent in intensity. Higher dosages are significantly more likely to result in states of Level 8A visual geometry over Level 8B.
DOB and other substituted amphetamines produce a full range of high-level hallucinatory states in a fashion that is more or less consistent and reproducible than that of many other commonly used psychedelics. These effects include:
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - In comparison to other psychedelics such as LSD, DOB is extremely high in internal hallucinations when approaching higher dosages. They are more common within dark environments and can be comprehensibly described through its variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
- External hallucinations - These are often present during the comedown and can include shadow people, among other indescribable beings. These external hallucinations are often lucid, interactive, autonomous, and robust. As sleep deprivation and stimulant psychosis surface, a trip sitter should accompany individuals sensitive to stimulants for the last part of the comedown. The visual effects of psychosis have been reported to blend into the psychedelic visuals around the 16-24 hour mark, sometimes accompanied by auditory hallucinations.
- Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring but seems only to be a prominent part of the experience among those who are already predisposed to synaesthetic states.
Transpersonal states are reported to be less consistent and reproducible than on other psychedelics like LSD or psilocybin mushrooms. This can perhaps be attributed to the noticeable physical and stimulating effects that this substance produces, which tends to interfere with the ability for the user to immerse themselves in the experience fully.
Internationally, DOB is a Schedule I drug under the Convention on Psychotropic Substances.
- Shulgin, A., & Shulgin, A. (1991). Erowid Online Books: "PIHKAL" - #62 DOB. Retrieved April 14, 2017.
- DOB and Other Possible Prodrugs | http://www.cognitiveliberty.org/shulgin/blg/2005/05/dob-and-other-possible-prodrugs.html
- Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. https://doi.org/10.1007/BF03161089
- "Erste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019.
- "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
- "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
- Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
- http://isap.sejm.gov.pl/DetailsServlet?id=WDU20111050614 2011$06$08&min=1
- 1717 CheMall OR025133
- 1717 CheMall OR182126
- A&J Pharmtech AJ-154472
- A&J Pharmtech AJ-20676
- abcr AB115961
- ABI Chemicals AC1Q1GY2
- AK Scientific 568764
- AK Scientific D764
- AKos AKOS001434143
- Alfa Aesar A13545
- Alfa Chemistry ACM89861
- Alichem A015037797
- ALK ALG00006256
- Amadis Chemical A843354
- Ambeed A105508
- American Custom Chemicals Corp CHM0019547
- Angene AG-K-79733
- Angene AGN-PC-0JK5VS
- Anward ANW-39377
- AOKBIO AB4272
- AOKChem AB4272
- Apollo Scientific Limited OR4893
- Ark Pharm, Inc. AK-88714
- Aromsyn AS00962
- Atomax jiji07455
- Aurora Fine Chemicals A00.537.738
- Aurora Fine Chemicals K02.108.063
- BePharm 2,4-Dihydroxybenzoic acid
- BePharm B23045
- BGS International BG00600767
- BGS International BG01499734
- BGS International BG04454642
- Bide Pharmatech BD23045
- BindingDB 74208
- BIONET-Key Organics DS-18507
- Biosynth W-100355
- Biosynth Carbosynth FD34721
- BLDpharm BD23045
- BOC Sciences 89-86-1
- Cambridge Chem B23045
- Cambridge Chem CC23063
- Cambridge Structural Database CCDC reference 245900
- Cambridge Structural Database CCDC reference 245901
- Cambridge Structural Database CCDC reference 245902
- Cambridge Structural Database CCDC reference 245903
- Cambridge Structural Database CCDC reference 747943
- Cambridge Structural Database CCDC reference 747944
- Cambridge Structural Database CCDC reference 747945
- Cambridge Structural Database CCDC reference 820616
- CambridgeSoft Corporation 8357
- ChemAdvisor OHS69010
- ChemAdvisor OHS69010
- ChEMBL CHEMBL328910
- Chembo Pharma KB-17590
- ChemDB 3964728
- ChemDB 6139974
- ChemDB 7123144
- Chemenu CM157314
- ChemIDplus 000089861
- ChemIDplus 001125582
- ChemIDplus 017289702
- ChemIDplus 020936327
- ChemIDplus 020936338
- ChemIDplus 032628050
- ChemIDplus 041453503
- ChemIDplus 154903374
- ChemIDplus 89861
- ChemScene 89-86-1
- Chemspace CSC000212172
- ChemSynthesis 14509
- Collaborative Drug Discovery 948137
- Crystallography Open Database (COD) 4500158
- CSDeposition Service DB02839
- DiscoveryGate 1491
- DiscoveryGate 183143
- DiscoveryGate 205066
- DiscoveryGate 328147
- DiscoveryGate 62915
- DrugBank DB02839
- DTP/NCI 13564
- DTP/NCI 169726
- DTP/NCI 305801
- DTP/NCI 4740
- Egon Willighagen
- eMolecules 502528
- Enamine EN300-06121
- eNovation Chemicals D409457
- EPA DSSTox 229_NTPBSI_v2b
- EPA DSSTox DTXCID205074
- FDA UNII - NLM LU39SC9JYL
- FDA UNII - NLM UNII: LU39SC9JYL
- Finetech Industry FT-0614326
- Fluorochem 209146
- Food and Agriculture Organization of the United Nations 2,4-Dihydroxybenzoic acid
- Food and Agriculture Organization of the United Nations 4099
- FooDB FDB000842
- Glentham Life Sciences GK3564
- Human Metabolome Database HMDB0029666
- Human Metabolome Database HMDB29666
- iChemical EBD2224190
- Infotherm 12805
- J&K Scientific 580184
- Jalor-Chem I01-1418
- Jean-Claude Bradley Open Melting Point Dataset 14018
- Jean-Claude Bradley Open Melting Point Dataset 16980
- Journal of Heterocyclic Chemistry 19850529_X03
- King Scientific KSC0004TS
- King Scientific KSC448I6H
- LabNetwork LN00225288
- Laboratory Chemical Safety Summary 1491
- Labseeker SC-25753
- LeadScope LS-1901
- Letopharm LT0323863
- Life Chemicals F1995-0247
- MassBank JP007230
- Mcule MCULE-8411449236
- Merck Millipore 1952
- Merck Millipore 800738
- MMDB 1855.3
- MMDB 50772
- MMDB 55943
- MMDB 55944
- MMDB 785.3
- MMDB 786.3
- Molport MolPort-001-641-037
- MP Biomedicals 207652
- MuseChem R070480
- NIAID 018062
- NIST Chemistry WebBook 3282258011
- NIST Spectra mainlib_162412
- NIST Spectra nist ri
- NIST Spectra replib_229676
- NIST Spectra replib_287111
- NIST Spectra replib_5192
- NMRShiftDB 20035560
- ONSChallenge ONS-mp:2,4-dihydroxybenzoic_acid
- Otava Chemicals 2829700
- Otava Chemicals 2829700.0
- Otava Chemicals 7993
- OXchem AX8023045
- Paragos 500011
- Parchem – fine & specialty chemicals 38757
- Parchem – fine & specialty chemicals 7137
- PDB DOB
- Phenol-Explorer 431
- Phion 21011472
- PubChem 1491
- PubMed 1107218
- PubMed 11235874
- PubMed 11324622
- PubMed 11393710
- PubMed 11453777
- PubMed 11572595
- PubMed 11600045
- PubMed 13159453
- PubMed 1416914
- PubMed 15216516
- PubMed 15264898
- PubMed 15779927
- PubMed 15907696
- PubMed 16482528
- PubMed 17061836
- PubMed 1736291
- PubMed 17374941
- PubMed 17381146
- PubMed 1794414
- PubMed 2385090
- PubMed 2826422
- PubMed 2827066
- PubMed 2931335
- PubMed 3085219
- PubMed 4027959
- PubMed 446414
- PubMed 5250038
- PubMed 6182571
- PubMed 9827415
- R&D Chemicals 6047
- Rosewachem RW063060
- Royal Society of Chemistry b506784g
- Royal Society of Chemistry b703292g
- Royal Society of Chemistry B814440K
- Royal Society of Chemistry b904748d
- Royal Society of Chemistry c000473a
- Royal Society of Chemistry DOI 10.1039/b9nj00353c (CCDC reference 747945)
- Ryan Scientific 047-73375
- Santa Cruz Biotechnology sc-238335
- Serum Metabolome Database HMDB0029666
- Shanghai Race Chemical RV508210066
- Sigma-Aldrich ALDRICH-D109401
- Sigma-Aldrich ALDRICH-W379808
- Sigma-Aldrich D109401
- Sigma-Aldrich V900767
- Sigma-Aldrich VETEC-V900767
- Sigma-Aldrich W379808
- Specs AE-562/41921969
- Springer Nature Oxidative Properties of Quinolinium Dichromate
- Springer Nature Separation and Determination of Phenolcarboxylic Acids by Capillary Zone Electrophoresis with Dynamic Preconcentration on Hypercrosslinked Polystyrene
- SynQuest 2629-1-26
- TCI D0568
- The Merck Index Online cs000000015991
- Thieme Chemistry 10.1055/s-0034-1378684
- Thomson Pharma 00018863
- Thomson Pharma 00077822
- Tractus Company Limited TR-032903
- Tractus Company Limited TRA0094558
- Urine Metabolome Database HMDB0029666
- Vitas-M STK299216
- VulcanChem VC293361
- Wikidata Q209206
- Wikipedia 2,4-Dihydroxybenzoic acid
- Wikipedia 2,4-Dihydroxybenzoic_acid
- Wonderchem WD04C3Q
- ZINC ZINC00388544
- zjartschem ZCF08538
Information made possible with:
- PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
- Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
- PubChem National Center for Bio Informatics
- Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.
Data is constantly updated so please check back later to see if there is any more available information on this substance.